Back to top

Analyst Blog

Leading provider of healthcare products for women Hologic Inc. (HOLX - Analyst Report) is scheduled to exhibit some of its newest offerings at the annual meeting of the European Society of Radiology, during Mar 7-11, in Vienna, Austria. This offers an ideal platform for the company to showcase its most recent products at the largest radiological meeting in Europe – the European Congress of Radiology (ECR).

Hologic will display its extensive suite of healthcare solutions for the screening and diagnosis of breast cancer, breast biopsy, osteoporosis risk assessment, medical MRI coils and extremity imaging. Management is enthusiastic about its breast tomosynthesis program including the introduction of a tomosynthesis biopsy option for the company’s Affirm breast biopsy guidance system. Hologic will also conduct education sessions and training workshops for tomosynthesis-guided breast biopsy.

The company received the European CE Mark for its Selenia Dimensions breast tomosynthesis system in 2008 following the U.S. Food and Drug Administration approval in 2011. Apart from Selenia system and the most recent innovation for the 3D technology platform – a tomosynthesis biopsy option for the 'Affirm breast biopsy guidance system', Hologic will also present its latest version of C-View software. These offerings are expected to improve standards of patient care and workflow efficiencies.

Moreover, Hologic is set to display two new products at ECR, namely Selenia Dimensions Avia Package and Flouroscan InSight-FD Mini C-arm. While the Avia Package provides cost effective 2D screening and diagnostic solutions, the Mini C-arm will meet the needs of orthopedic and extremity surgeons by improving workspace access and ease of positioning.  

Given that ECR hosts more than 20,000 participants representing the medical specialty of radiology across Europe and the Mediterranean, the exhibition presents a unique opportunity to create brand awareness for Hologic and thereby promote its innovative products.

The coherent focus on Selenia is encouraging following the ongoing shift from Hologic’s legacy Selenia product lines. According to the company, its breast tomosynthesis technology is ‘game-changing’. Notably, expectations from the technology are sky-high. However, over the past few quarters, Hologic witnessed several challenges in the form of economic uncertainties in Europe, slower sales cycles and increasing pricing pressure.

In the light of these facts, the estimates for the ongoing fiscal have remained stagnant over the last 90 days. Accordingly, the stock carries a Zacks Rank #3 (Hold). While we remain on the sidelines for Hologic, other medical stocks such as Cyberonics (CYBX - Analyst Report), Given Imaging and Medical Action , each carrying a Zacks Rank #1 (Strong Buy) are expected to do well.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%